Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection

Pediatric Infectious Disease Journal

Volumn 22, Issue 7, 2003, Pages 668-670

  Rosso, Raffaella ^a   Di Biagio, Antonio ^a   Ferrazin, Antonio ^a   Bassetti, Matteo ^a   Ciravegna, Barbara Wenda ^a   Bassetti, Dante ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Children; Human immunodeficiency virus; Lactic acidosis

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; MUSCLE WEAKNESS; PRIORITY JOURNAL; RESPIRATORY FAILURE; T LYMPHOCYTE SUBPOPULATION; VERTICAL TRANSMISSION;

EID: 0041343208     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000076600.83640.3e     Document Type: Article

References (26)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
3. Brinkman K, Ter Hofstede HJ. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: lactic acidosis, risk factors and therapeutic options. AIDS Rev 1999;1:141-8.
4. John M, Moore CB, James IR, et al. Chronic hyperlactacidemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23.
5. Harris M, Tesiorowski A, Chan K, et al. Lactic acidosis complicating antiretroviral therapy: frequency and correlates. Antiviral Ther 2000;5:31.
6. Fortgang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
7. Boubaker K, Sudre P, Flepp M, et al. Hyperlactatemia and antiretroviral therapy in the Swiss HIV Cohort Study [Abstract 57]. Presented at the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2, 2000.
8. Boxwell DE, Styrt BA. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors [Abstract M22]. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999.
9. Ter Hofstede HJ, de Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 2000;11:611-16.
10. Wooltorton E. HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. Can Med Assoc J 2002;166:1067-8.
11. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: a case report. AIDS 1997;11:1294-6.
12. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999;354:1084-9.
13. Giaquinto C, De Romeo A, Giacomet V, et al. Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission. AIDS 2001;15:1074-5.
14. European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-7.
15. Avi Lemberg D, Palasanthiran P, Goode M, et al. Tolerabilities of antiretrovirals in paediatric HIV infection. Drug Saf 2002;25:973-91.
16. Church JA, Mitchell WG, Gonzalez-Gomez I, et al. Mitochondrial DNA depletion, near-fatal metabolic acidosis, and liver failure in an infected child treated with combination antiretroviral therapy. J Pediatr 2001;138:748-51.
17. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
18. Roge BT, Calbet J, Muller K, et al. Mitochondrial function and exercise capacity in HIV infected patient with lipodystrophy [Abstract TuPp 1232]. Presented at the XII International AIDS Conference, Durban, July 9 to 14, 2000.
19. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in a HIV patient: a case report. AIDS 1997;11:1294-6.
20. Sundar K. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patient and review of the literature. Crit Care Med 1997;8:1425-30.
21. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-7.
22. Boffito M, Marietti G, Audagnotto S, et al. Lactacidemia in Asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2002;34:558-9.
23. Rosso R, Di Biagio A, De Macina I, et al. Lattacidemia in bambini con infezione da HIV-1 a trasmissione verticale in terapia antiretrovirale [oral session]. Presented at the XVI Convegno Nazionale AIDS e Sindromi Correlate, Torino, November 23 to 26, 2002.
24. Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis 2001;33:1914-21.
25. Boubaker K, Flepp M, Sudre P, et al. Hyperlactacidemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 2001;33:1931-7.
26. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003;22:77-84.